Abstract:Immune cell activation triggers signaling cascades leading to transcriptional reprogramming, but also strongly impacts on the cell’s metabolic activity to provide energy and biomolecules for inflammatory and proliferative responses. Macrophages activated by microbial pathogen-associated molecular patterns and cytokines upregulate expression of the enzyme ACOD1 that generates the immune-metabolite itaconate by decarboxylation of the TCA cycle metabolite cis-aconitate. Itaconate has anti-microbial as well as immunomodulatory activities, which makes it attractive as endogenous effector metabolite fighting infection and restraining inflammation. Here, we first summarize the pathways and stimuli inducing ACOD1 expression in macrophages. The focus of the review then lies on the mechanisms by which itaconate, and its synthetic derivatives and endogenous isomers, modulate immune cell signaling and metabolic pathways. Multiple targets have been revealed, from inhibition of enzymes to the post-translational modification of many proteins at cysteine or lysine residues. The modulation of signaling proteins like STING, SYK, JAK1, RIPK3 and KEAP1, transcription regulators (e.g. Tet2, TFEB) and inflammasome components (NLRP3, GSDMD) provides a biochemical basis for the immune-regulatory effects of the ACOD1-itaconate pathway. While the field has intensely studied control of macrophages by itaconate in infection and inflammation models, neutrophils have now entered the scene as producers and cellular targets of itaconate. Furthermore, regulation of adaptive immune responses by endogenous itaconate, as well as by exogenously added itaconate and derivatives, can be mediated by direct and indirect effects on T cells and antigen-presenting cells, respectively. Taken together, research in ACOD1-itaconate to date has revealed its relevance in diverse immune cell signaling pathways, which now provides opportunities for potential therapeutic or preventive manipulation of host defense and inflammation.

Itaconate boosts malaria via induction of PD-L1

Itaconate impairs immune control of Plasmodium by enhancing mtDNA-mediated PD-L1 expression in monocyte-derived dendritic cells

Itaconate as a potential target for antimalarial therapy

Itaconate is a Lysosomal Inducer That Promotes Antibacterial Innate Immunity.

Itaconate Uptake Via SLC13A3 Improves Hepatic Antibacterial Innate Immunity

Itaconate Regulates Macrophage Function Through Stressful Iron-Sulfur Cluster Disrupting And Iron Metabolism Rebalancing

The Emerging Application of Itaconate: Promising Molecular Targets and Therapeutic Opportunities.

The immunometabolite itaconate inhibits heme synthesis and remodels cellular metabolism in erythroid precursors

The Cell Autonomous and Non-Autonomous Roles of Itaconate in Immune Response

PD-1 Expression on NK Cells in Malaria-Exposed Individuals is Associated with Diminished Natural Cytotoxicity and Enhanced Antibody-Dependent Cellular Cytotoxicity

A Molecular Signature in Blood Reveals a Role for P53 in Regulating Malaria-Induced Inflammation.

Itaconate drives mtRNA-mediated type I interferon production through inhibition of succinate dehydrogenase

Itaconate: the poster child of metabolic reprogramming in macrophage function

Itaconate: A Metabolite Regulates Inflammation Response and Oxidative Stress

Itaconate modulates mitochondria for antiviral IFN-β

Synergistic blockade of TIGIT and PD-L1 increases type-1 inflammation and improves parasite control during murine blood-stage Plasmodium yoelii non-lethal infection

Metabolite itaconate in host immunoregulation and defense

Metabolic Messengers: itaconate

Control of immune cell signaling by the immuno-metabolite itaconate

Endogenously produced itaconate negatively regulates innate-driven cytokine production and drives global ubiquitination in human macrophages

Cancer cell-intrinsic biosynthesis of itaconate promotes tumor immunogenicity